Stock IXI IXICO PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:20 2024-07-04 am EDT 		5-day change 1st Jan Change
7 GBX -1.75% Intraday chart for IXICO plc -1.75% -44.00%
Jun. 19 Ixico Bags Over GBP1 Million Contract for Parkinsonian Disorder Study MT
Jun. 19 AIM WINNERS & LOSERS: Ixico and Light Science Technologies win deal AN

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024
Capitalization 1 23.92 45.68 38.52 16.13 9.187 3.385
Enterprise Value (EV) 1 16.66 37.95 32.43 10.36 5.156 1.985
P/E ratio 55.4 x 48.5 x 25.6 x 16.5 x -7.79 x -1.27 x
Yield - - - - - -
Capitalization / Revenue 3.16 x 4.79 x 4.19 x 1.87 x 1.38 x 0.65 x
EV / Revenue 2.2 x 3.98 x 3.53 x 1.2 x 0.77 x 0.38 x
EV / EBITDA 33.3 x 29.2 x 19.1 x 6.91 x -6.44 x -0.95 x
EV / FCF - - - - -3.1 x -0.74 x
FCF Yield - - - - -32.2% -136%
Price to Book - - - - - -
Nbr of stocks (in thousands) 46,902 47,091 48,151 48,151 48,351 48,351
Reference price 2 0.5100 0.9700 0.8000 0.3350 0.1900 0.0700
Announcement Date 12/4/19 12/2/20 12/7/21 12/7/22 12/5/23 -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024
Net sales 1 7.561 9.532 9.19 8.643 6.665 5.2
EBITDA 1 0.5 1.3 1.7 1.5 -0.8 -2.1
EBIT 1 0.364 0.856 1.181 0.908 -1.437 -2.9
Operating Margin 4.81% 8.98% 12.85% 10.51% -21.56% -55.77%
Earnings before Tax (EBT) 1 0.366 0.858 1.16 0.885 -1.361 -2.9
Net income 1 0.432 0.952 1.575 1.035 -1.178 -2.7
Net margin 5.71% 9.99% 17.14% 11.98% -17.67% -51.92%
EPS 2 0.009200 0.0200 0.0312 0.0203 -0.0244 -0.0550
Free Cash Flow 1 - - - - -1.661 -2.7
FCF margin - - - - -24.92% -51.92%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 12/4/19 12/2/20 12/7/21 12/7/22 12/5/23 -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2022 S1 2024 S1 2024 S2
Net sales 1 - - 2.661
EBITDA 1 - - -0.774
EBIT 1 - - -1.276
Operating Margin - - -47.95%
Earnings before Tax (EBT) - - -
Net income 1 0.216 -1.413 -1.251
Net margin - - -47.01%
EPS 0.004300 -0.0292 -
Dividend per Share - - -
Announcement Date 5/24/22 5/21/24 -
1GBP in Million
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024
Net Debt 1 - - - - - -
Net Cash position 1 7.26 7.73 6.09 5.77 4.03 1.4
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - - - -1.66 -2.7
ROE (net income / shareholders' equity) - - - - -9.85% -31.1%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - - - - - -
Capex 1 0.52 1.14 2.15 2.25 1.96 0.6
Capex / Sales 6.84% 11.98% 23.44% 25.97% 29.45% 11.54%
Announcement Date 12/4/19 12/2/20 12/7/21 12/7/22 12/5/23 -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for IXICO plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IXICO PLC Stock IXICO plc
-44.00% 4.4M
MODERNA, INC. Stock Moderna, Inc.
+16.59% 44.44B
LONZA GROUP AG Stock Lonza Group AG
+41.02% 39.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.62% 37.68B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.92% 31.46B
CELLTRION, INC. Stock Celltrion, Inc.
-9.23% 27.02B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.34% 26.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+41.53% 13.8B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.49% 12.46B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.40% 11.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IXI Stock
  4. Financials IXICO plc